4DMedical Ltd (ASX: 4DX) shares are charging higher today.
Again.
Shares in the S&P/ASX 200 Index (ASX: XJO) respiratory imaging technology company closed on Friday trading for $3.97. In early afternoon trade on Tuesday, with the ASX having been shuttered on Monday for the King's Holiday, shares are swapping hands for $4.13 apiece, up 4%.
For some context, the ASX 200 is down 0.4% at this same time.
Taking a step back, 4D Medical shares are now up an eye-popping 1,276.7% over the past 12 months, compared to a 1.4% gain delivered by the benchmark index.
And it was thanks to this rapid share price gain, and the resulting market cap surge, that 4DMedical stock was included in the ASX 200 back on 20 April.
To put the past year's gains into better perspective, if you'd invested $10,000 in the ASX 200 healthcare stock 12 months ago, you'd be sitting on $137,667 today.
And looking ahead, MPC Markets' Mark Gardner forecasts more outperformance to come (courtesy of The Bull).
Here's why.
Image source: Getty Images
Should I buy 4DMedical shares today?
"4DMedical develops advanced respiratory imaging technology," Gardner explained.
Commenting on his bullish outlook for the ASX 200 healthcare stock, he said:
The company has attracted attention after securing commercial validation through relationships with GSK, Mayo Clinic and Philips, which support the case for broader adoption of its CT:VQ technology in the United States and other markets.
Sounding a word of caution, Gardner noted, "The shares remain volatile, and the business is still in the early stages of converting partnerships into material revenue."
Indeed, while 4DMedical shares are up a stellar 1,277% in 12 months, shares are down 9% in 2026. And that comes after they hit an all-time closing high of $6.80 each on 10 April.
But taking a long-term view, Gardner believes the company is still undervalued at current levels.
He concluded:
However, the company has a stronger funding position after its recent capital raise and a clearer commercial pathway than in prior years. We believe the market is undervaluing the longer-term opportunity at recent levels.
What's the latest from the ASX 200 healthcare stock?
4DMedical shares closed up 18.9% on 29 May after the company announced that it had inked a commercial agreement with US-based SimonMed Imaging for the immediate clinical deployment of its CT:VQ technology.
Commenting on the agreement on the day, 4DMedical CEO and founder Andreas Fouras said:
SimonMed is one of the largest and most influential outpatient imaging providers in the United States. Their decision to adopt CT:VQ, moving directly to commercial deployment, is a major milestone for 4DMedical and a strong validation of both our technology and our clinical value.
